Drug Profile
Research programme: kainate receptor antagonists - Biotie Therapies
Alternative Names: E099-255011; GluR5 receptor antagonists; GluR6 receptor antagonistsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator elbion GmbH
- Developer biocrea GmbH
- Class Indoles; Small molecules
- Mechanism of Action Kainic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in Germany
- 14 Nov 2008 elbion GmbH has been acquired by BioTie Therapies
- 04 Sep 2008 Early research in Neurodegenerative disorders in Germany (unspecified route)